Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Capital Leases (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 5 years of Capital Leases data on record, last reported at $30.1 million in Q4 2025.

  • For Q4 2025, Capital Leases fell 3.1% year-over-year to $30.1 million; the TTM value through Dec 2025 reached $30.1 million, down 3.1%, while the annual FY2025 figure was $30.1 million, 3.1% down from the prior year.
  • Capital Leases reached $30.1 million in Q4 2025 per MRVI's latest filing, down from $30.4 million in the prior quarter.
  • Across five years, Capital Leases topped out at $55.9 million in Q1 2021 and bottomed at $30.1 million in Q4 2025.
  • Average Capital Leases over 4 years is $37.2 million, with a median of $31.4 million recorded in 2024.
  • Peak YoY movement for Capital Leases: decreased 2.48% in 2024, then decreased 3.1% in 2025.
  • A 4-year view of Capital Leases shows it stood at $55.3 million in 2021, then plummeted by 42.35% to $31.9 million in 2023, then decreased by 2.48% to $31.1 million in 2024, then fell by 3.1% to $30.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Leases were $30.1 million in Q4 2025, $30.4 million in Q3 2025, and $30.7 million in Q2 2025.